logo
Share SHARE
FONT-SIZE Plus   Neg

Emergent BioSolutions Signs Deal With VaxInnate On Pandemic Influenza Vaccine

Emergent BioSolutions Inc. (EBS) announced Friday that it has signed a license agreement with VaxInnate Corporation under which Emergent acquired the exclusive right to manufacture and sell VaxInnate's pandemic influenza vaccine candidate in the United States.

Emergent said VaxInnate will continue to develop its pandemic influenza vaccine candidate under its current BARDA contract and Emergent will manufacture the pandemic influenza vaccine candidate using flexible manufacturing technology.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
France-based optical-lens maker Essilor International SA (EL), Delfin and Ray-Ban maker Luxottica Group (LUX) Monday announced their plan to merge in a deal valued around $49 billion. Essilor would become a holding company with the new name "EssilorLuxottic." Uncertainty has become the name of the game, as the new president is set to assume office. Groundwork is being done for major policy overhauls, with the first step towards repealing the Obamacare taken, as Senators voted 51-48 to approve a budget resolution for achieving the same. The House is set to... A country's productivity is measured by dividing its gross domestic product or GDP in U.S. dollars and normalized to purchasing power parities by the total number of hours worked by the country's workforce in a year. It is considered as a key driver of long-term economic growth and living standards. CLICK...
comments powered by Disqus
Follow RTT